Hepatocyte growth factor (HGF) exerts biological activity through the Met receptor tyrosine kinase. HGF plays essential roles in the embryonic development of the liver and placenta, and in the migration of myogenic precursor cells. In mature tissues, HGF plays roles in tissue protection and regeneration, including in the liver and kidney. HGF participates in invasion, metastasis, and drug resistance. Drug development targeting HGF-Met has been challenging. One focus has been the use of recombinant HGF as a biological drug and another has been the use of HGF-Met inhibitors for cancer treatment. Clinical trials using HGF or HGF-Met inhibitors are ongoing. 
I. Introduction
In 1984, hepatocyte growth factor (HGF) was reported to be a mitogenic protein for hepatocytes in primary culture. The primary structure of HGF became evident with cDNA cloning in 1989, when HGF was identified as a novel growth factor. A scatter factor was identified as a fibroblast-derived factor that enhances motility and the spreading of epithelial cells, and in 1991, it was found to be identical to HGF. Likewise, in 1991 the purification of a fibroblast-derived growth factor that targets a variety of epithelial cells independently revealed that it was identical to HGF. 
II. Structure of HGF and the Met receptor
HGF is a heterodimeric molecule composed of an α-chain and a β-chain, which are linked by one disulfide bridge (Fig. 1A) . HGF is biosynthesized as a prepro-form of 728 amino acids, including a signal sequence and both α-and β-chains. After cleavage of a signal peptide of the first 31 amino acids, a single-chain HGF is further cleaved between Arg494 and Val495, and this resulted in the formation of a two-chain mature HGF. Single-chain HGF is biologically inactive and processing into a two-chain form is coupled to its activation. Several serine proteases, mainly HGF activator, urokinase-type plasminogen activator, matriptase, and hepsin are responsible for the processing of HGF. There are various forms of HGF such as those produced through the alternative splicing of HGF mRNA. A variant with five amino acids deleted in the first kringle domain is the second major form of HGF. N-terminal smaller variants consisting of the N-terminal hairpin and the first kringle domains (designated NK1) and the N-terminal hairpin plus the first and second kringle domains (designated NK2) are naturally biosynthesized variants of HGF, though expression of these variants is either very low or restricted in some cell lines.
The Met receptor is composed of structural domains, the extracellular Sema, PSI (the similar structure is found in the plexins, semaphorins and integrins) and IPT (a similar structure is found in the immunoglobulin-like fold shared by plexins and transcriptional factor) domains, the transmembrane domain, the intracellular juxtamembrane, and tyrosine kinase domains (Fig. 1B) . HGF exhibits a 50% homology to an amino acid sequence in HGF-like protein. HGF and HGF-like protein contain four kringle domains in the α-chain.
HGF-like protein specifically binds and activates Ron receptor tyrosine kinase, a family of the Met receptor.
Binding of HGF to the Met receptor induces the phosphorylation of tyrosine residues in the activation loop of a tyrosine kinase domain, which results in the activation of tyrosine kinase and the subsequent phosphorylation of tyrosine residues in the C-terminal multifunctional docking site. Phosphorylation of the C-terminal tyrosine residues plays a critical role in both the direct and indirect recruitment of various intracellular signal transducers (Fig. 1B) .
Association of the adapter protein Gab-1 (Grb2-associated binding protein 1) with Met provides docking platforms for the further binding of signaling molecules, which leads to biological responses that are unique to the HGF-Met pathway.
NK1 and NK2 bind the Met receptor as smaller N-terminal variants of HGF. NK1 serves a minimum set of domains that are responsible for high-affinity binding of HGF to the Met receptor, while β-chain binds to the Met with a lower affinity compared with the α-chain.
The extracellular complex structure between HGF and Met was proposed using structural analyses such as small-angle X-ray scattering (Fig. 1C ). NK1 and NK2 exhibit antagonistic activity on HGF-induced mitogenesis, while they function as agonists in terms of cell motility activity. NK4 is composed of an N-terminal hairpin and four kringle domains, and it binds to Met but does not activate Met, thereby being antagonistic to HGF. been determined. The crystal structures for the NK1 dimer, the complex structures of β-chain and Sema + PSI domains, and tyrosine kinase domains are shown in Fig. 2. 
III. Biological activities
HGF exhibits multiple biological activities in a wide variety of cells ( 
IV. Developmental roles
The essential roles of HGF in the development of mammalian fetal tissues have been defined via the targeted disruption of either HGF or the Met receptor gene using knockout mice that are embryonically lethal due to impaired organogenesis of the placenta and liver.
In the placenta, the number of epithelial trophoblasts in the labyrinthine layer is markedly reduced, leading to an impaired exchange of oxygen and nutrients between the maternal and embryonic blood streams. The embryonic liver is reduced in size and shows extensive apoptotic cell death, indicating that hepatoblasts/hepatocytes in the embryonic liver require HGF for proliferation and/or survival.
Activation of the HGF-Met pathway plays a decisive role in the generation of skeletal muscle that is derived from long-range migrating muscle precursor cells. In Met HGF is known to be a mesenchymal-derived paracrine factor that supports the morphogenesis of developing epithelia during the organogenesis of the lung, kidney, and tooth.
In the nervous system, HGF has chemoattractant-like functions. Developing axons can be guided to their targets by diffusible molecules and factors bound to the cell surface that act either as chemoattractants or repellents. Transplanted limb buds attract motor axons in 7 amphibians and birds. In a similar manner, explanted mouse limb bud mesenchyme attracts the axons of motor neurons. HGF has been identified as a chemoattractant factor that is derived from the limb bud mesenchyme. The developmental and morphogenic roles of HGF are summarized in Table 2 .
V. Physiological functions
Regeneration of the liver is a dramatic phenomenon in higher animals. When 70% of the liver is resected, the cells in the remaining liver rapidly proliferate, and the original liver mass is restored within a week. HGF was initially implicated as a hepatotrophic factor that enhances liver regeneration, and the hepatotrophic role of HGF has been definitively demonstrated in a variety of experimental hepatic disease models. Likewise, HGF plays physiological roles in the regeneration and/or protection of various tissues, as demonstrated in different types of disease models in different tissues (Table 2) .
A conditional knockout of the Met gene in mice has helped to define the roles of the HGFMet pathway in tissue protection and repair (Table 3) . Hepatocytes subjected to selective loss of functional Met are highly susceptible to cell death even after mild liver injury, indicating that the anti-apoptotic activity of HGF plays a role in protection of the liver.
Liver-or hepatocyte-specific Met -/-mice have shown delayed liver regeneration associated with persistent inflammatory reaction, and are susceptible to fibrotic change in the liver.
After bile duct ligation, hepatocyte-specific Met -/-mice were more susceptible to chronic inflammation and fibrotic change compared with control mice. The effects shown by these liver-or hepatocyte-specific Met -/-mice indicate the physiological roles of the HGF-Met pathway in the protection, regeneration, anti-inflammation, and anti-fibrosis of the liver.
In addition to the liver, characterizations of a variety of conditional Met knockout mice indicate that the HGF-Met pathway plays important roles in the regeneration, protection, and homeostasis in various cells and tissues (Table 3) . For instance, a loss of functional Met in renal tubules had no appreciable defect in renal function, but when tubular cell-specific Met -/-mice were subjected to renal injury, they displayed a higher serum creatinine, more severe morphologic lesions, and increased apoptosis compared with control mice.
In podocyte-specific Met -/-mice, no pathology was seen, but the mice developed more 
VII. Therapeutic approaches using HGF
Based on the evidence that activation of the Met receptor leads to tissue protection and repair against tissue injury, but also to invasive and metastatic progression of cancer cells in tumor tissues, two distinct therapeutic approaches can be considered: one is application of HGF, i.e., Met-agonist, for treatment of organ injuries; and the other is application of inhibitory molecules against the HGF-Met pathway to inhibit cancer invasion and metastasis.
Experiments to explore the therapeutic potential of HGF in the treatment of diseases have been performed in various disease models in different tissues (Table 2) . Administration of human recombinant HGF into mice or rats stimulates the proliferation of hepatocytes after liver insult caused by partial hepatectomy or hepatotoxins. Through its anti-apoptotic action, HGF has been used to abrogate the onset of acute hepatitis and fulminant hepatic failure. Likewise, the administration of HGF has accelerated tissue regeneration and/or attenuated tissue injury in other organs. HGF has suppressed the onset of acute renal failure caused by the administration of nephrotoxic drugs or renal ischemia. HGF administered to rats with cardiac ischemia-reperfusion injury has reduced the extent of apoptosis in cardiac myocytes, thereby reducing the infarcted area.
Chronic inflammatory diseases are characterized by fibrotic changes in tissues, including liver cirrhosis, chronic renal failure, lung fibrosis, and cardiomyopathy. These fibrotic diseases are progressive and currently incurable. Administration of HGF into rats with liver cirrhosis has been used to decrease the accumulation of hepatic extracellular matrix components, thereby abrogating the mortality rate due to hepatic dysfunction. HGF has prevented renal fibrosis and the concomitant renal dysfunction in models of chronic renal failure or renal fibrosis. Although mechanisms responsible for the anti-fibrotic action of HGF are not fully understood, HGF suppresses the expression of transforming growth factor-β, a key growth factor during the onset of tissue fibrosis, while HGF enhances the protease activities responsible for the degradation of extracellular matrix components, including matrix metalloproteinases.
The neurotrophic actions of HGF have been expanded to include therapeutic approaches for the treatment of injury or diseases of the nervous system. An infusion of HGF into the brain has been used to prevent neuronal death in the hippocampus and in the cerebral cortex.
Intrathecal administration of HGF has suppressed disease progression and prolonged the life span in rat models for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons and the degeneration of motor axons. Likewise, the intrathecal administration of HGF has been used to promote functional recovery after spinal cord injury in the common marmoset. 
